# P53 Mutational Status and cf HPV DNA for the Management of HPV-associated OPSCC

> **NCT03077243** · PHASE2 · COMPLETED · sponsor: **UNC Lineberger Comprehensive Cancer Center** · enrollment: 195 (actual)

## Conditions studied

- Carcinoma, Squamous Cell
- Head and Neck Neoplasms
- Oropharyngeal Neoplasms

## Interventions

- **RADIATION:** Intensity Modulated Radiotherapy (IMRT)
- **DRUG:** Cisplatin (or alternative)
- **PROCEDURE:** Assessment for surgical evaluation

## Key facts

- **NCT ID:** NCT03077243
- **Lead sponsor:** UNC Lineberger Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12
- **Primary completion:** 2022-12-14
- **Final completion:** 2022-12-14
- **Target enrollment:** 195 (ACTUAL)
- **Last updated:** 2024-05-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03077243

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03077243, "P53 Mutational Status and cf HPV DNA for the Management of HPV-associated OPSCC". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03077243. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*